Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients
References (34)
- et al.
Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with 18F-2-deoxyglucose in affective illness
J Affect Dis
(1986) - et al.
Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone
Psychiatry Res
(1979) - et al.
Distribution of effects of haloperidol on energy metabolism in the rat brain
Brain Res
(1982) - et al.
15O positron emission tomographic scanning in predominantly never treated acute schizophrenic patients
Lancet
(1983) - et al.
Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F18
Arch Gen Psychiatry
(1985) - et al.
Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease
Ann Neurol
(1985) The middle evoked response components and schizophrenia
Schizophr Bull
(1977)- et al.
Cerebral glucography with positron tomography
Arch Gen Psychiatry
(1982) - et al.
Cerebral metabolic consequences of electrical stimulation in normal individuals
Human Neurobiol
(1983) - et al.
Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders
Arch Gen Psychiatry
(1984)
Selected aspects of amine and receptor hypothesis of affective illness
J Clin Psychopharmacol
Research in endorphins and schizophrenia
Schizophr Bull
Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients
Am J Psychiatry
Positron emission tomography in schizophrenic patients with and without neuroleptic medication
J Cereb Blood Flow Metab
BMDP Statistical Software
Behavioral correlates of activity in basal ganglia neurons
Trend Neurosci
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
Science
Cited by (161)
Reprint of: <sup>F-18</sup>Fluorodeoxyglucose positron emission tomography studies of the schizophrenia spectrum: The legacy of Monte S. Buchsbaum, M.D.
2019, Psychiatry ResearchCitation Excerpt :Buchsbaum et al. (1987) extended the visual identification methods of DeLisi et al. (1985b) by using a stereotaxic approach to identify the regions of interest. Buchsbaum et al. reported that basal ganglia GMR increased with medication, more in the putamen than in the caudate; however, similar to DeLisi et al. (1985b), the cortical anteroposterior ratio, an index of relative hypofrontality, was unaffected by neuroleptics (Buchsbaum et al., 1987). Up until this point, prior studies were confounded by order effects, doctor's choice of neuroleptic medications and doses, and a lack of placebo-controlled and blinded ratings.
<sup>F-18</sup> Fluorodeoxyglucose positron emission tomography studies of the schizophrenia spectrum: The legacy of Monte S. Buchsbaum, M.D.
2019, Psychiatry ResearchCitation Excerpt :The thalamus, a major cortical relay from the limbic system with many important frontal lobe connections, is of major interest in schizophrenia. Results from early FDG-PET studies of the thalamus in schizophrenia, (e.g., Buchsbaum et al., 1987; Resnick et al., 1988; Wiesel et al., 1987) were mixed, which was thought to be due to medication status, varied FDG-uptake conditions, or methodological issues with defining the thalamus visually vs. stereotaxically. In 1996, Buchsbaum et al. published the first evidence of reduced thalamic GMR in a never-medicated schizophrenia sample during the sustained-attention CPT (Buchsbaum et al., 1996).
Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry
2010, Psychiatry Research - NeuroimagingAn fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia
2009, Psychiatry Research - NeuroimagingCorrelation between prepulse inhibition and cortical perfusion during an attentional test in schizophrenia. A pilot study
2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry